DK1303495T3 - Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet - Google Patents
Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitetInfo
- Publication number
- DK1303495T3 DK1303495T3 DK01952859.5T DK01952859T DK1303495T3 DK 1303495 T3 DK1303495 T3 DK 1303495T3 DK 01952859 T DK01952859 T DK 01952859T DK 1303495 T3 DK1303495 T3 DK 1303495T3
- Authority
- DK
- Denmark
- Prior art keywords
- substituted
- alkylnylpyrimidines
- disorders
- neurotrophic activity
- senility
- Prior art date
Links
- 230000000508 neurotrophic effect Effects 0.000 title 1
- 206010015037 epilepsy Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22034800P | 2000-07-24 | 2000-07-24 | |
| PCT/US2001/023088 WO2002008205A1 (en) | 2000-07-24 | 2001-07-20 | Substituted 5-alkynyl pyrimidines having neurotrophic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1303495T3 true DK1303495T3 (da) | 2010-09-20 |
Family
ID=22823191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01952859.5T DK1303495T3 (da) | 2000-07-24 | 2001-07-20 | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7205297B2 (da) |
| EP (1) | EP1303495B1 (da) |
| JP (2) | JP5154728B2 (da) |
| AT (1) | ATE469132T1 (da) |
| AU (1) | AU2001273574A1 (da) |
| CA (1) | CA2416442C (da) |
| DE (1) | DE60142236D1 (da) |
| DK (1) | DK1303495T3 (da) |
| ES (1) | ES2346513T3 (da) |
| WO (1) | WO2002008205A1 (da) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003222738B2 (en) | 2002-05-07 | 2009-09-17 | Neurosearch A/S | Novel azacyclic ethynyl derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| US7531529B2 (en) | 2003-06-05 | 2009-05-12 | Roche Palo Alto Llc | Imidazole derivatives |
| ES2358512T3 (es) | 2003-06-12 | 2011-05-11 | F. Hoffmann-La Roche Ag | Derivados de imidazol, sustituidos por heteroarilo como antagonistas del receptor de glutamato. |
| JP2007502298A (ja) * | 2003-08-14 | 2007-02-08 | スミスクライン ビーチャム コーポレーション | 化合物 |
| JP2007517006A (ja) * | 2003-12-24 | 2007-06-28 | アストラゼネカ アクチボラグ | Ｔｉｅ２（ｔｅｋ）活性のあるピリミジン |
| ES2317079T3 (es) * | 2003-12-24 | 2009-04-16 | Astrazeneca Ab | Pirimidinas con actividad tie2 (tek). |
| BRPI0511678A (pt) | 2004-06-01 | 2008-01-08 | Hoffmann La Roche | piridin-4-il-etinil-imidazóis e pirazóis como antagonistas de receptor de mglu5 |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| KR20070086188A (ko) * | 2004-11-17 | 2007-08-27 | 미카나 테라퓨틱스, 인크. | 키나제 억제제 |
| US20100048543A1 (en) * | 2005-02-01 | 2010-02-25 | Astrazeneca Ab | Pyrimidine compounds having ties (tek) inhibitory activity |
| WO2006106721A1 (ja) * | 2005-03-30 | 2006-10-12 | Shionogi & Co., Ltd. | チロシンキナーゼ阻害作用を有するピリミジン誘導体 |
| BRPI0616630B8 (pt) * | 2005-09-30 | 2021-05-25 | Miikana Therapeutics Inc | compostos de pirazol substituídos |
| WO2008076883A2 (en) | 2006-12-15 | 2008-06-26 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
| ES2577391T3 (es) | 2006-12-21 | 2016-07-14 | F. Hoffmann-La Roche Ag | Polimorfos de un antagonista del receptor mglur5 |
| JP2010529193A (ja) * | 2007-06-11 | 2010-08-26 | ミイカナ セラピューティクス インコーポレイテッド | 置換ピラゾール化合物 |
| CN104975020B (zh) * | 2008-02-11 | 2020-01-17 | 菲奥医药公司 | 经修饰的RNAi多核苷酸及其用途 |
| WO2010008582A2 (en) | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
| TW201010984A (en) | 2008-07-29 | 2010-03-16 | Boehringer Ingelheim Int | 5-alkynyl-pyrimidines |
| US8470834B2 (en) | 2008-08-20 | 2013-06-25 | Merck Sharp & Dohme Corp. | AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| AU2009282567B2 (en) | 2008-08-20 | 2014-10-02 | Merck Sharp & Dohme Corp. | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| AU2009282574B2 (en) | 2008-08-20 | 2014-08-21 | Merck Sharp & Dohme Corp. | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| TW201020245A (en) | 2008-08-20 | 2010-06-01 | Schering Corp | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| EP2949752B1 (en) | 2008-09-22 | 2017-12-20 | RXi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
| US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
| WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| EP2440053A4 (en) | 2009-06-09 | 2012-10-31 | California Capital Equity Llc | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF |
| CN102573480B (zh) | 2009-06-09 | 2015-06-10 | 加利福尼亚资本权益有限责任公司 | 三嗪衍生物及其治疗应用 |
| JP5770198B2 (ja) * | 2009-10-30 | 2015-08-26 | ヤンセン ファーマシューティカ エヌ．ベー． | オピオイド受容体調節因子としてのフェノキシ置換ピリミジン |
| US8633183B2 (en) | 2010-01-26 | 2014-01-21 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| UY33198A (es) * | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
| EP3578183B1 (en) | 2010-03-24 | 2021-09-08 | Phio Pharmaceuticals Corp. | Rna interference in ocular indications |
| WO2011119887A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
| RU2615143C2 (ru) | 2010-03-24 | 2017-04-04 | Адвирна | Самодоставляющие PHKi соединения уменьшенного размера |
| UA110995C2 (uk) * | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
| EP3079707A4 (en) | 2013-12-02 | 2017-10-18 | RXi Pharmaceuticals Corporation | Immunotherapy of cancer |
| CN105960265A (zh) | 2013-12-04 | 2016-09-21 | 阿克赛医药公司 | 利用经化学修饰的寡核苷酸处理伤口愈合的方法 |
| CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
| JP2017514908A (ja) | 2014-05-01 | 2017-06-08 | アールエックスアイ ファーマシューティカルズ コーポレーション | 核酸分子を利用する目の前部における障害の処置のための方法 |
| US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
| JP6983752B2 (ja) | 2015-07-06 | 2021-12-17 | フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. | スーパーオキシドディスムターゼ１（ｓｏｄ１）を標的とする核酸分子 |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
| EP4055167A2 (en) | 2019-11-08 | 2022-09-14 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy |
| EP4085136A1 (en) | 2019-12-31 | 2022-11-09 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides with improved systemic delivery |
| CN118043459A (zh) | 2021-08-04 | 2024-05-14 | 菲奥医药公司 | 经化学修饰的寡核苷酸 |
| WO2023015264A1 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2691655A (en) | 1952-05-24 | 1954-10-12 | Burroughs Wellcome Co | 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same |
| GB951431A (en) | 1959-03-17 | 1964-03-04 | Wellcome Found | Pyrimidine derivatives and the manufacture thereof |
| US3862190A (en) | 1972-09-08 | 1975-01-21 | Pfizer | 5-(unsubstituted and substituted phenoxy)-4-amino pyrimidines |
| DK397574A (da) | 1973-08-24 | 1975-04-28 | Ciba Geigy Ag | |
| GB1523274A (en) | 1974-08-05 | 1978-08-31 | Ici Ltd | Herbicidal compositions containing substituted pyrimidine |
| FR2358148A1 (fr) | 1976-07-12 | 1978-02-10 | Dick Pr | Derives de 2,4-diaminopyrimidines et leur mise en solution en association avec des sulfamides |
| FR2397407A2 (fr) | 1977-07-11 | 1979-02-09 | Dick Pierre | Derives de 2,4-diamino pyrimidines et leur mise en solution en association avec des sulfamides |
| EP0079312A3 (de) * | 1981-11-11 | 1984-04-25 | Ciba-Geigy Ag | Heterocyclische Acetylenverbindungen |
| US4663334A (en) | 1985-12-11 | 1987-05-05 | Mcneilab, Inc. | Heteroaromatic acetylenes useful as antihypertensive agents |
| FI895821A0 (fi) | 1988-12-07 | 1989-12-05 | Wellcome Found | Farmaceutiskt aktiva cns foereningar. |
| GB9012316D0 (en) * | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| IE912114A1 (en) | 1990-07-02 | 1992-01-15 | Union Pharma Scient Appl | Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present |
| US5075305A (en) | 1991-03-18 | 1991-12-24 | Warner-Lambert Company | Compound, composition and use |
| US5250532A (en) | 1991-04-11 | 1993-10-05 | Dowelanco | 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides |
| HUT65177A (en) | 1991-04-17 | 1994-05-02 | Pfizer | Process for producing antitumor activity enhancing pyrimidine derivatives and pharmaceutical preparations containing them |
| US5336677A (en) | 1991-10-24 | 1994-08-09 | American Home Products Corporation | Substituted aminopyrimidines as antihypertensives |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| WO1994014780A1 (en) | 1992-12-18 | 1994-07-07 | The Wellcome Foundation Limited | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
| EP0688325A1 (en) | 1993-03-08 | 1995-12-27 | Eisai Co., Ltd. | Phosphonic acid derivatives |
| ATE163647T1 (de) | 1993-08-26 | 1998-03-15 | Ono Pharmaceutical Co | 4-aminopyrimidin derivate |
| JPH08283246A (ja) | 1994-06-01 | 1996-10-29 | Nippon Soda Co Ltd | ピリミジン誘導体、その製造方法及び有害生物防除剤 |
| CA2217034A1 (en) | 1995-04-03 | 1996-10-10 | Sumitomo Pharmaceuticals Company, Limited | Novel pyrimidine derivatives effective as psychotropic drug and process for the production thereof |
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| US6440965B1 (en) * | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
-
2001
- 2001-07-20 EP EP01952859A patent/EP1303495B1/en not_active Expired - Lifetime
- 2001-07-20 DE DE60142236T patent/DE60142236D1/de not_active Expired - Lifetime
- 2001-07-20 CA CA2416442A patent/CA2416442C/en not_active Expired - Fee Related
- 2001-07-20 ES ES01952859T patent/ES2346513T3/es not_active Expired - Lifetime
- 2001-07-20 US US10/333,447 patent/US7205297B2/en not_active Expired - Lifetime
- 2001-07-20 AU AU2001273574A patent/AU2001273574A1/en not_active Abandoned
- 2001-07-20 DK DK01952859.5T patent/DK1303495T3/da active
- 2001-07-20 JP JP2002514111A patent/JP5154728B2/ja not_active Expired - Lifetime
- 2001-07-20 WO PCT/US2001/023088 patent/WO2002008205A1/en active Application Filing
- 2001-07-20 AT AT01952859T patent/ATE469132T1/de not_active IP Right Cessation
-
2012
- 2012-06-11 JP JP2012132101A patent/JP2012229218A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2416442C (en) | 2010-06-08 |
| JP5154728B2 (ja) | 2013-02-27 |
| AU2001273574A1 (en) | 2002-02-05 |
| US20040087789A1 (en) | 2004-05-06 |
| JP2004504386A (ja) | 2004-02-12 |
| CA2416442A1 (en) | 2002-01-31 |
| JP2012229218A (ja) | 2012-11-22 |
| ES2346513T3 (es) | 2010-10-18 |
| DE60142236D1 (de) | 2010-07-08 |
| WO2002008205A1 (en) | 2002-01-31 |
| EP1303495B1 (en) | 2010-05-26 |
| US7205297B2 (en) | 2007-04-17 |
| EP1303495A1 (en) | 2003-04-23 |
| ATE469132T1 (de) | 2010-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1303495T3 (da) | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet | |
| ATE377592T1 (de) | Neurotropische substituierte pyrimidine | |
| IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
| EA200701296A1 (ru) | 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства | |
| AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
| DE122005000044I2 (de) | R-Enantiomer des N-Propargyl-1-Aminoindan zur Behandlung verschiedener Krankheiten und Mesylat, Esylat und Sulfat davon | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| EA200200183A1 (ru) | Композиция, содержащая трамадол и противосудорожное лекарственное средство | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| ATE253918T1 (de) | Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel | |
| CY1105507T1 (el) | Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες | |
| BR9908084A (pt) | Composto, processo para tratar um paciente afligido por algum distúrbio do sistema nervoso central e periférico, composição farmacêutica, e, uso de um composto | |
| TNSN06403A1 (en) | 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | |
| SG157231A1 (en) | Substituted p-diaminobenzene derivatives | |
| DE69807587D1 (de) | Quinazolin-4-on AMPA Antagonisten | |
| EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
| MX2007007472A (es) | Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c. | |
| EA200601607A1 (ru) | Сульфонамидные соединения для лечения нейродегенеративных расстройств | |
| ATE439363T1 (de) | Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides | |
| BR9803385A (pt) | AtropisÈmeros de 2,3-dissubstituìdo-(5,6)-heteroaril condensado-pirimidin-4-onas. | |
| AP9901473A0 (en) | Use of benzopyranols to treat neurological disorders. | |
| IL136306A (en) | Bis (fluorophenyl) alkylamides and related compounds, pharmaceutical compositions comprising them and their use in treating neurological disease or disorder | |
| WO2003037260A3 (en) | Methods and compositions for treating parkinson's disease | |
| EP1640359A3 (en) | Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides | |
| WO2003090771A3 (en) | Diagnostics and therapeutics for diseases associated with trace amine receptor 3(ta3) |